Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
View Patent ↗The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazopyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), neurodegenerative diseases (e.g., Alzheimer's disease), metabolic diseases (e.g. diabetes), neurodevelopmental disorders (e.g. autism), or psychiatric disorders (e.g. schizophrenia or anxiety)) as well as methods of treating these diseases.
1. A compound of Formula (Ia):
or a pharmaceutically acceptable form thereof, wherein
X 1 , X 2 , and X 3 are independently N or C;
X 4 and X 5 are independently N or CR 4 ;
wherein at least one of X 1 , X 2 , X 3 , X 4 , and X 5 is N;
X 7 is CR 10 ;
X 8 is CR 11 ;
is a single or double bond, as valency allows;
R 2 , R 3 , R 5 , R 6 , R 7 , R 8 , and R 9 , are independently hydrogen, halogen, optionally substituted aliphatic, —CN, —OR, —SR, —N(R) 2 , —NO 2 , —C(O)R, —CO 2 R, —C(O)NROR, —OC(O)R, —C(O)NH 2 ;
R 1 is independently —C(O)R, —CO 2 (optionally substituted C 1-6 aliphatic), —CO 2 (optionally substituted heteroaryl), —CO 2 (optionally substituted heterocyclyl), or —OC(O)(optionally substituted C 1-6 aliphatic);
R 10 and R 11 are each independently hydrogen, halogen, optionally substituted aliphatic, —CN, —OR, SR, —N(R) 2 , —NO 2 , —C(O)R, —CO 2 R, or —C(O)NROR;
each R is independently hydrogen or optionally substituted C 1-6 aliphatic optionally substituted heteroaryl, or optionally substituted heterocyclyl; and
each R 4 is independently hydrogen, halogen, or optionally substituted C 1-6 aliphatic; and
R 6 and R 7 , or R 7 and R 8 , may be optionally taken together to form an optionally substituted 5-6 membered fused heterocyclic or 5-6 membered fused heteroaryl ring.
2. The compound of claim 1 , wherein the compound is of Formula (Ia-i):
or a pharmaceutically acceptable form thereof.
3. The compound of claim 1 , wherein the compound is of Formula (Ib-i) or (Ib-ii):
or a pharmaceutically acceptable form thereof, wherein
X 1 , X 2 , and X 3 are independently N or C;
X 4 and X 5 are independently N or CR 4 ;
wherein at least one of X 1 , X 2 , X 3 , X 4 , and X 5 is N;
X 7 is CH;
X 8 is CH;
is a single or double bond, as valency allows;
R 1 is —C(O)R, wherein R is an optionally substituted heterocyclyl;
R 2 , R 3 , R 6 , and R 7 are independently —H, —F, —Cl, —CN, —CH 3 , —CF 3 , —CHF 2 , —C(O)NH 2 , —OH, —OC 1-4 alkyl, or —OCF 3 ; or R 6 and R 7 are taken together to form a 5-6 membered fused heterocyclyl or 5-6 membered fused heteroaryl; and
each R 4 is independently hydrogen or C 1-6 alkyl.
4. The compound of claim 1 , wherein R 7 is —CN.
5. The compound of claim 1 , wherein R 2 , R 3 , or R 6 is hydrogen.
6. The compound of claim 1 , wherein both R 2 and R 3 are hydrogen.
7. The compound of claim 1 , wherein R 2 is —N(R N ) 2 and R 3 is hydrogen, wherein each instance of R N is independently hydrogen, or optionally substituted C 1-6 aliphatic.
8. The compound of claim 1 , wherein R 2 is —OR O and R 3 is hydrogen, wherein R O is hydrogen, or optionally substituted C 1-6 aliphatic.
9. The compound of claim 1 , wherein R 1 is —C(O)R, wherein R is one of the following:
10. The compound of claim 1 , wherein the compound is of Formula (II), (III), (IV), (V), (VI), or (VII):
11. The compound of claim 1 , wherein the compound is selected from the group consisting of:
and pharmaceutically acceptable forms thereof.
12. A composition comprising a compound of claim 1 , or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient.
13. The composition of claim 12 , wherein the composition comprises a kinase inhibitor selected from a PI3K inhibitor and an mTOR inhibitor.
14. A method of inhibiting MNK1 and/or MNK2 in a cell comprising administering to a cell a compound of claim 1 , or a pharmaceutically acceptable form thereof.
15. A method of treating leukemia comprising administering to a subject in need of treatment a compound of claim 1 .
16. The method of claim 15 , wherein the compound is administered in combination with a kinase inhibitor selected from a PI3K inhibitor and an mTOR inhibitor.
17. The method of claim 15 , wherein the compound is administered at a dosage level sufficient to deliver from about 0.001 mg/kg to about 100 mg/kg to a subject in need thereof.
18. A method of treating leukemia comprising administering to a subject in need of treatment a composition of claim 12 .